NCI Stock Soars (NCIT)

NEW YORK ( TheStreet) -- Shares of NCI (Nasdaq: NCIT) have taken a tremendous swing upward. The stock is trading at $4.17 as of 10:40 a.m. ET, 22.6% above Tuesday's closing price of $3.40. Volume is at 172,474, two times the daily average of 88,200.

NCI has a market cap of $29.1 million and is part of the technology sector and computer software & services industry. Shares are down 71.9% year to date as of the close of trading on Tuesday.

NCI, Inc. provides information technology (IT) and professional services and solutions to the United States Federal Government defense, intelligence, and civilian agencies. The company has a P/E ratio of five, equal to the average computer software & services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates NCI as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full NCI Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

null

More from Markets

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids